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Silvia de Sanjose, PhD,16,17 F. Xavier Bosch, PhD1,18Introduction: Human papillomavirus−vaccinated cohorts, irrespective of age, will likely reduce
their subsequent screening requirements, thus opening opportunities for global cost reduction and
program sustainability. The determinants of uptake and completion of a 3-dose human papilloma-
virus vaccination program by adult women in a European context were estimated.
Study design: This was an intervention study.
Setting/participants: Study participants were women aged 25−45 years, attending opportunistic
or population-based cervical cancer screening in Belgium, Denmark, Finland, France, Germany,
Slovenia, Spain, Sweden, and the United Kingdom between April 2016 and May 2018.
Intervention: Study participants completed a questionnaire on awareness and attitudes on adult
female human papillomavirus vaccination and were invited to receive free human papillomavirus
vaccination.
Main outcome measures: Main outcome measures were acceptance, uptake, and completion of
vaccination schedule. Determinants of vaccine uptake were explored using multilevel logistic mod-
els in 2019.
Results: Among 3,646 participants, 2,748 (range by country=50%−96%) accepted vaccination,
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April 2021higher vaccine acceptance were previous awareness of adult female (OR=1.22, 95% CI=1.00, 1.48)
and male (OR=1.59, 95% CI=1.28, 1.97) vaccination. Women in stable relationships (OR=0.56,
95% CI=0.45, 0.69) or with higher educational level (OR=0.76, 95% CI=0.63, 0.93) were more likely
to refuse vaccination. Recruitment by postal invitation versus personal invitation from a healthcare
professional resulted in lower vaccine acceptance (OR=0.13, 95% CI=0.02, 0.76). Vaccination cover-
age of >70% of adolescent girls in national public programs was of borderline significance in pre-
dicting human papillomavirus vaccine uptake (OR=3.23, 95% CI=0.95, 10.97). The main reasons
for vaccine refusal were vaccine safety concerns (range=30%−59%) and the need for more informa-
tion on human papillomavirus vaccines (range=1%−72%). No safety issues were experienced by
vaccinated women.
Conclusions: Acceptance and schedule completion were largely dependent on recruitment
method, achieved coverage of national vaccination programs, and personal relationship status.
Knowledge of benefits and safety reassurance may be critical to expanding vaccination target ages.
Study results suggest that there are no major opinion barriers in adult women to human papilloma-
virus vaccination, especially when vaccination is offered face to face in healthcare settings.
Trial Registration: EudraCT Number 2014-003177-42.
Am J Prev Med 2021;60(4):478−487. © 2020 American Journal of Preventive Medicine. Published by Elsevier
Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).INTRODUCTIONCervical cancer is an important health problem inEurope with about 60,000 new cases and 25,000deaths per year.1 The highest burdens are
observed in Central and Eastern Europe,1 which can
largely be ascribed to the absence of screening, historical
differences in coverage, quality of national screening
programs, or differences in human papillomavirus
(HPV) exposure.2,3
Novel methods for cervical cancer detection include
clinically validated HPV tests. These show a higher sen-
sitivity and negative predictive values than cytology.4,5
Furthermore, they are processed by automatic or semi-
automatic instruments, which increases throughput,
eliminates the subjectivity of cytology, and enhances
program quality assurance.6
Although initially indicated for adolescent girls only,
HPV vaccines continue to expand their licensing, clinical
indications, and dosing regimens. These include vaccina-
tion of both male and female individuals aged >40 years,7
vaccination of immunocompromised groups,8 vaccina-
tion at the time of treatment of cervical intraepithelial
neoplasia Grades 2 and 3 and adenocarcinoma in situ,9
vaccination for recurrent respiratory papillomatosis
cases,9 and 2-dose regimens in those aged <15 years.10
However, national programs are mainly offering vacci-
nation to a few cohorts of adolescent girls per year.11
The HPV-FASTER strategy proposes programs
including an HPV screening visit and treatment if
required, in combination with broad-spectrum HPVvaccination to adult women.12 This could facilitate better
detection and early intervention against prevalent dis-
ease and protection against future infection. These inter-
ventions should potentially reduce subsequent screening
needs. However, this strategy is not free of uncertainties.
These include vaccine acceptance by adult women,
safety, and reduced effectiveness compared with those
among younger women.7,13 Currently, European Union
vaccine licensing does not include an upper age limit,14
−16 and the U.S. Food and Drug Administration recently
extended the upper limit to age 45 years.17,18 However,
to date, no formal recommendations to expand target
ages for vaccination beyond age 26 years have been
issued.
Only a few highly heterogeneous studies on willing-
ness to have HPV vaccination among the adult popula-
tion have been conducted in Europe, where uptake
remains anecdotal.11,19−23 To the best of the authors’
knowledge, no study in adult women has explored how
HPV vaccination could be integrated with screening,
and none have assessed uptake and completion rates of
the full 3-dose schedule.
Comparing Health Services Interventions for the Pre-
vention of HPV-Related Cancer project (COHEAHR) is
a European Union−funded consortium investigating the
opportunities for cervical cancer prevention by means of
strategic protocols of HPV screening and vaccination
(www.coheahr.eu). Within this project, COHEAHR-
WP4 is a multinational study conducted in 9 European
countries (Belgium, Denmark, Finland, France, Ger-
many, Slovenia, Spain, Sweden, and the United
480 Robles et al / Am J Prev Med 2021;60(4):478−487Kingdom [UK]) aimed to identify global and regional
determinants of HPV vaccine acceptability and comple-
tion rates as well as logistics and programmatic issues of
vaccinating adult women attending routine cervical can-
cer screening.METHODS
Study Population
Intended recruitment per country was 250−300 women aged
25−45 years (age range varying by country) and not previ-
ously vaccinated against HPV. Spain was to recruit an addi-
tional 150 underscreened women (i.e., not screened in the last
5 years). Participants self-completed a questionnaire on socio-
demographics, medical history, attitude toward screening,
awareness and opinion on HPV vaccine, and vaccine accept-
ability. They were also asked to select from predefined
answers, those relevant to their decision on vaccine acceptabil-
ity or to complete an open field question (Appendix Text 1,
available online). Those who accepted vaccination and were
eligible were offered free vaccination except in the UK, where
HPV vaccine could not be administered owing to ongoing
changes in the call−recall system of the cervical cancer screen-
ing program affecting planned population-based recruitment.
Participants were followed for a 6-month period for comple-
tion of the 3-dose vaccine schedule and safety data collection.
Noneligibility criteria for HPV vaccination included current or
planned pregnancy within the following months, allergy or
hypersensitivity to any vaccine component, history of immune
disease, or hysterectomy. HPV vaccination was also offered to
women unwilling to complete the questionnaire. HPV vaccines
used in the study were provided at no cost by GlaxoSmithK-
line Biologicals SA (Cervarix) and Sanofi Pasteur MSD (Gar-
dasil and Gardasil9, whose current Marketing Authorization
Holder is Merck Sharp and Dohme). The choice of vaccine
used in each country was based on existing national priorities
in their public programs.
Each country used the same core protocol and data collection
forms, but each national coordinator chose the strategy to recruit
and vaccinate adult women that would best fit the existing screen-
ing efforts in their country (Table 1). Participating countries with
population-based cervical cancer screening programs (Denmark
and Sweden) invited women to participate in the study as if they
were invited to get screened (population-based approach). On the
basis of age and place of residency, potentially eligible women
were identified using screening or census registries and invited
through postal letters that included the questionnaire. Therefore,
the randomly selected population potentially included noneligible
women already vaccinated or pregnant, breastfeeding, or planning
to become pregnant soon. Eligible women were asked to return
the completed questionnaire and, if they accepted vaccination, to
arrange a visit at a vaccination center. The remaining countries
with opportunistic screening and the UK used convenience
recruitment by inviting women attending healthcare or screening
services for cervical screening through brochures, posters, health-
care providers, or phone calls to recently screened women. If not
available, recruitment sites were provided with fridges, thermome-
ters, and protocols for vaccine storage and temperature control.
Germany invited HPV-screened women included in theWolfsburg pilot project for better cervical cancer prevention with
primary HPV screening.24 Recruitment took place between April
2016 and May 2018. The inclusion of 250−300 women per coun-
try allowed estimating acceptance, uptake, and completion rate
with a minimum precision of §6.2%.
Ethical approvals were obtained by local IRBs and the Ministry
of Health, where applicable. All participants provided free and
written informed consent.
Measures
Irrespective of recruitment method, study participants were
defined as women who either completed the questionnaire or
accepted vaccination without completion of the questionnaire.
Study vaccination outcomes were estimated for (1) acceptance
(proportion of women willing to be vaccinated in the question-
naire), (2) uptake (proportion of women who actually were vacci-
nated), and (3) completion rate (proportion of women who
completed the 3-dose vaccine schedule).
Statistical Analysis
The heterogeneity observed between study sites (Table 1) and par-
ticipant characteristics (Appendix Table 1, available online) were
used to explore the effect of context and individual factors on vac-
cine uptake. The main characteristics assessed at the site level
included the recruitment method (population-based versus conve-
nience) and the national or regional immunization program char-
acteristics obtained from published reports.25−33 Included were
vaccination coverage in targeted adolescent girls categorized as
low (<50%) or high (>70%); whether catch-up vaccination cam-
paigns had been conducted in the country, suggesting that target
participants might have already been offered HPV vaccination;
and whether the country had already implemented male vaccina-
tion programs. Individual characteristics included age (in quin-
tiles), being in a stable relationship, foreign-born status, education
level, and knowledge of HPV vaccine (ever heard of it and aware
of the eligibility of adult women and boys for HPV vaccination).
Among women completing the questionnaire, the effect of
individual and site characteristics on vaccine uptake was explored
using stepwise-multilevel logistic regression analysis with individ-
uals (first level) nested within sites (second level).34 Model A
incorporated only site-specific random effects to model variation
in vaccine uptake between sites by means of intraclass correlation
on the basis of the latent response formulation.35 The intraclass
correlation assesses the individuals’ variation in vaccine uptake at
the site level so that values close to 0% inform a very low or null
effect of site on vaccine uptake. Model B included individual cova-
riates to explore the potential association of individual-level varia-
bles, and Model C additionally included the contextual variables.
Results are reported as AORs with 95% CIs as well as predicted
probabilities.
Statistical significance was set at p<0.05, and statistical analyses
were carried out using Stata, version 15.1, and R, version 3.2.3.
Analyses were conducted in 2019.
RESULTS
Response rates (including completed questionnaires or rea-
sons for nonparticipation) in the 2 countries with a popula-
tion-based approach were 34.4% of 1,932 invitations inwww.ajpmonline.org
Table 1. Study Site Characteristics by Country
Country Ages, years HPV vaccine Recruitment Source Invitation











>70 and <50 Yes No
Denmark 30‒45 4HPVv Pop based Screening registry (Greater
Copenhagen area)
Postal letter <50 Yes No
Finland 25‒35 2HPVv
9HPVv






France 25‒45 4HPVv Convenience OB/GYN public practice
(Reims)
HCP criteria <50 Yes No






Slovenia 25‒45 9HPVv Convenience OB/GYN public practice
(Litija and Nova Gorica)
HCP criteria <50 No No
Spain 25‒45 2HPVv
9HPVv




HCP criteria >70 No No
Sweden 25‒45 9HPVv Pop based Population registry
(Stockholm county)
Postal letter >70 Yes No
UK 30‒45 NAc Convenience England GP practices
(n=253)
Posters with link to an
online questionnaire
>70 Yes No
aNational immunization program characteristics were obtained from certain sources.25−33 Coverage targeted girls refers to the achieved HPV vaccination coverage achieved during the study recruit-
ment period in young girls/Catch-up campaign refers to the potential targeting of study participants in previous catch-up campaigns/Boys vaccination refers to the implementation of HPV vaccination
in boys within the national immunization program at the time of the study.
bIn the participating sites in Finland, women and men might have been targeted and vaccinated as part of a large cluster-randomized trial.
cNA because UK conducted a questionnaire-only study.
2HPVv, bivalent vaccine (Cervarix); 4HPVv, quadrivalent vaccine (Gardasil); 9HPVv, nonavalent vaccine (Gardasil 9); GP, general practitioner; HCP, healthcare providers; HPV, human papillomavirus; NA,
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(Appendix Figure 1, available online).
In all countries, 4,137 women replied to the invitation,
328 refused to participate, and 161 completed the ques-
tionnaire despite already being vaccinated and therefore
ineligible. In total, 3,648 eligible women participated in
the study (Table 2), 9 of whom only participated in the
vaccination component.
All recruiting countries achieved or surpassed their
recruitment target except France owing to clinic work-
load and recruitment overestimation.
The HPV vaccine was accepted by 2,748 women
(range by country=50%−96%) (Table 2). Among study
participants, 20 acceptors and 151 refusers of vaccina-
tion were ineligible for vaccination. Reasons for not get-
ting vaccinated among acceptors were not collected.
However, in countries with convenience sampling,
uptake was only slightly lower than acceptance rates
where vaccination was scheduled for a date different
from that of study invitation (50%−93% uptake). In
Denmark and Sweden, 19 (9.9%) and 78 (40.2%), respec-
tively, women who accepted vaccination in the question-
naire did not schedule an appointment for vaccine
administration. By age, vaccine uptake was higher
among women aged <30 years (78.4% vs 67.5%).
In multivariate multilevel analysis (Table 3), lower
uptake was observed among women in stable relation-
ships (OR=0.56, 95% CI=0.45, 0.69) and those with a
higher education level (OR=0.76, 95% CI=0.63, 0.93).
Women who already knew that the HPV vaccine could
be administered to adult women and boys showed a
higher uptake (OR=1.22, 95% CI=1.00, 1.48 and
OR=1.59, 95% CI=1.28, 1.97, respectively). Age and for-
eign-born status did not show an effect on vaccine
uptake.
Regarding site characteristics, the invitation to partici-
pate by post resulted in lower HPV vaccine uptake than
on-site face to face invitation (OR=0.13, 95% CI=0.02,
0.76). Sites with high vaccination program coverage of
young girls also showed higher uptake (OR=3.23, 95%
CI=0.95, 10.97). This became stronger (OR=4.57, 95%
CI=1.33, 15.70) after the removal of German data. The
addition of site-level characteristics into the model did
not change the participant-level associations obtained
but reduced the variance between sites (intraclass corre-
lation).
Completion of 3 doses in vaccinated women (Table 2)
was ≥85% in all countries except in France (58%). Rea-
sons for noncompliance among vaccinated women were
loss to follow-up (n=108, 56.0%), personal decision to
discontinue (n=53, 27.5%), pregnancy (n=19, 9.8%),
availability-related reasons (e.g., lack of time and change
of residence; n=10, 5.2%), and concurrent cancerdiagnosis (n=3, 1.6%). Of note, 6 women who became
pregnant continued with vaccination after ceasing
breastfeeding.
Predefined reasons for accepting or refusing vaccina-
tion (Appendix Text 1, available online) were collected
for all sites except Sweden, where the only reasons for
vaccine refusal were collected. A total of 2,522 acceptors
and 658 refusers provided the reasons for their decision,
whereas 26 (1%) and 240 (27%) did not reply.
The most cited reasons to accept vaccination
(Figure 1A) were vaccine efficacy (85%−97%) and the
seriousness of cervical cancer (89%−100%). Of note,
only 49% and 55% of Danish and German women,
respectively, chose vaccine safety as a reason to get vacci-
nated. Other reasons for vaccine acceptance mentioned
by ≥5 women were previous or current HPV infection
or HPV-related conditions (n=13) and having relatives
or friends with cervical or other cancers (n=10).
Reasons for refusing vaccination are provided for all
countries combined owing to small numbers in some
countries (Figure 1B). The most cited reason for refusing
vaccination was safety concerns (country range=30%
−59%). No reply was <15% in most countries except in
Spain (23%), Sweden (37%), and Slovenia (43%). The
need for more information was especially relevant in
France (69%) and the UK (72%), although on the basis
of low numbers (13 and 18 refusers, respectively).
French (85%) and Belgian (27%) women needed to con-
sult other people before being vaccinated.
Other reasons for vaccine refusal mentioned by ≥5
women were being in a stable relationship (n=9), previ-
ous or current HPV infection or HPV-related conditions
(n=6), and needing more time to decide (n=6).
Of the 808, 495, and 848 participants vaccinated with
the bivalent, quadrivalent, and nonavalent vaccine,
respectively, 1,921 (89.3%) returned the safety card, with
649 reporting any adverse event, more than half of
which were injection-site related (n=347). There were 2
serious adverse events, a sinus thrombosis and a skull
fracture, neither was considered related to the vaccine.DISCUSSION
In this multicenter study in Europe, the average acceptability
of HPV vaccination among women attending cervical can-
cer screening was 75% (country range=50%−95%), and
vaccine uptake among participants was 66.9% (country
range=30%−92%).
The status of the adolescent public vaccination pro-
grams and the strategy used in this study to invite
women for free HPV vaccination played a major role in
vaccine uptake by adult women. Recruitment at health-
care service settings resulted in a high acceptance ofwww.ajpmonline.org







Subjects with ≥1 dose
administered,
n (%)




Belgium 308 261 (84.7) 238 (77.3) 204 (66.2)
Finland 510 459 (90.0) 443 (86.9) 421 (82.6)
France 63 50 (79.4) 50 (79.4) 29 (46.0)
Germany 323 305 (94.4) 299 (92.6) 254 (78.6)
Slovenia 610 303 (49.8) 303 (49.7) 290 (47.5)
Spain 693 569 (82.1) 564 (81.4) 513 (74.0)
UK 434 416 (95.9) NAa NAa
Population based
Denmark 347 191 (55.0) 145 (41.8) 141 (40.6)
Sweden 360 194 (53.9) 109 (30.3) 106 (29.4)
Total 3,648 2,748 (75.3) 2,151 (66.9)b 1,958 (60.9)b
aNA because UK conducted a questionnaire-only study.
bAmong 3,214 participating women excluding UK
NA, not applicable; UK, United Kingdom.
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However, acceptance by Slovenian sites (67% in Litija;
24% in Nova Gorica) reflects the variability in uptake
already observed in different regions in Slovenia in the
2016−2017 young girls immunization program (46.4%,
range=33.9%−78.3%).30 This is consistent with results
observed in Belgium, with high variability of vaccine
uptake in study participants (98% in Ghent; 55% in Brus-
sels), similar to the 90% and 35% uptake in young girls,25




Stable relationship (yes versus no) —
Education level (above versus up to
secondary education)
—
Previous awareness of adult female
vaccination (yes versus no)
—
Previous awareness of male
vaccination (yes versus no)
—
Context variables
Recruitment method (mail versus
convenience)
—
Local HPV vaccination coverage in





AIC, Akaike information criterion; HPV, human papillomavirus; ICC, intraclass
April 2021low-income countries and with lower SES in Brussels.
However, the high uptake in German adult women (93%)
is not concordant with the low uptake (around 40%) at
young ages in public programs.29 An explanation could
include being offered HPV vaccination face to face by the
doctor providing routine screening services and the strong
effect of their recommendation to get vaccinated.36,37
Significant individual factors associated with HPV
vaccine uptake included not being in a stable relation-
ship, lower education level, and previous awareness ofPV Vaccine Uptake Using Multilevel Logistic Regression
del with individual
characteristics,
Model with individual and site
characteristics,
OR (95%CI) OR (95%CI)
0.56 (0.45, 0.69) 0.56 (0.45, 0.69)
0.76 (0.62, 0.93) 0.76 (0.63, 0.93)
1.22 (1.01, 1.48) 1.22 (1.00, 1.48)
1.58 (1.28, 1.96) 1.59 (1.28, 1.97)
— 0.13 (0.02, 0.76)




Figure 1. Provided reasons for vaccine (A) acceptance or (B) refusal.
Note: Countries legend: BE, DK, DE, FI, FR, SI, SP, and UK. Predefined acceptance reasons explored were HPV vaccine is safe, Vaccine protects
against cervical cancer/genital warts (Efficacy), HPV vaccine is offered for free, It is recommended to get the HPV vaccine, and Cervical cancer is a
serious disease. Predefined refusals reasons explored were I am concerned about HPV vaccine safety/side effects, I am concerned about whether
the HPV vaccine works and how long it lasts (Efficacy), I do not like vaccines (Dislike vaccines), I do not have time (e.g., work’s schedule, transporta-
tion issues,...) (Lack of time), I feel I might not benefit from the HPV vaccine protection (No need), I have been personally advised not to get vacci-
nated (Others advice), I need more information, I need to consult other people.
BE, Belgium; DE, Germany; DK, Denmark; FI, Finland; FR, France; HPV, human papillomavirus; SI, Slovenia; SP, Spain; UK, United Kingdom.
484 Robles et al / Am J Prev Med 2021;60(4):478−487HPV vaccination indication for adult women or male
individuals. In agreement with study findings, being sin-
gle was also associated with higher acceptance in Swe-
den21 and Greece.23 Swedish and German women20 had
also shown a higher acceptance at lower education level,
but acceptance in Greece was lower in less educated
women. Theories for vaccine refusal in more educated
women include higher exposure to contradictory and
possibly inaccurate information regarding the HPV vac-
cine.38 In contrast to the observed lack of association for
age, multivariate analyses showed lower HPV acceptance
with increasing age in Germany and Greece probably
because of their recruitment of women up to age
65 years. To the best of the authors’ knowledge, no pre-
vious studies explored women’s awareness of HPV vac-
cine eligibility of adult women.
The main reasons for vaccine uptake were trust in
vaccine efficacy and perceived seriousness of cervical
cancer, whereas safety concerns and the need for more
information or consultation with other people were the
most cited reasons for refusal. This is consistent with the
qualitative findings in a European systematic reviewwhere men and women of all ages were asked about
HPV vaccine for adults and children.39
Therefore, to achieve high acceptance rates of the
HPV vaccine, irrespective of the targeted age groups of
the programs, it is important to involve healthcare pro-
viders in the invitation and to address the potential dis-
information and misinformation in the general
population regarding vaccine safety and efficacy.
COHEAHR-WP4 is a study conducted in Europe,
where there are occasional anti-vaccine movements
(negative publicity), and the burden of cervical cancer
and perceived risk is lower than in low-income coun-
tries. These study findings are consistent with prelimi-
nary results of a systematic review of HPV vaccine
acceptability by middle-aged women that suggests very
high and consistent acceptability in African and Latin
American countries (80% average) and a higher variability
in Asian populations (range by country=60%−80%).40
Africa and Latin America are regions with high incidence
and mortality rates of cervical cancer.
Countries in Central and Eastern Europe and low-/mid-
dle-income countries, where HPV vaccination will bewww.ajpmonline.org
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than routine HPV vaccination of 1 or few adolescent
cohorts. Extended age at vaccination could result in larger
impacts in a shorter period on the basis of available scien-
tific data.41,42 Furthermore, vaccination should signifi-
cantly reduce costs associated with screening frequency
and diagnostic and treatment procedures.12
In settings where HPV testing is feasible, the HPV-
FASTER strategy could tackle the limitations of cytol-
ogy-based screening programs by using HPV testing as a
screening tool, largely based on self-sampling proce-
dures, and moving toward an improved once-in-a-life-
time screening and vaccination visit if current trials
confirm the value of 1-dose vaccination also in middle-
aged women.43,44 In populations where compliance with
the follow-up of positive results is a major barrier, 1-visit
interventions (HPV vaccination combined with HPV
screen and treat) could be worth evaluating.45 Further-
more, data are accumulating showing that vaccination of
middle-aged women could potentially reduce transmis-
sion to their sexual partners46 and boost herd protec-
tion.47 If these results can be replicated, the HPV-
FASTER strategy could result in an additional reduction
of HPV infections and their consequences.
Limitations
This study allowed for exploration of 2 of the HPV-
FASTER strategy uncertainties: logistical challenges (how
to best integrate vaccine administration in already estab-
lished screening efforts) and societal challenges (whether
HPV vaccination is an accepted cervical cancer prevention
strategy when offered to adult women). However, the
adaptations in the integration of vaccination into each
regional or national screening services make the interpre-
tation and representativeness of overall study findings
somewhat challenging. The low response in countries
where invitation was done by postal mail might reflect a
lower acceptance among those who did not reply. By con-
trast, the convenience sampling in healthcare centers
might over-represent women with higher concerns for
their health and women interested in free HPV vaccina-
tion referred by friends or other study participants.CONCLUSIONS
Within the limitations of the study size in each coun-
try, the results suggest that there are no major opin-
ion barriers in the population to HPV vaccination of
adult women in several countries in Europe. Accep-
tance and completion of the vaccination program are
especially high when free vaccination is offered face
to face by healthcare professionals and strongly
dependent on the recruitment method used, coverageApril 2021achieved by national HPV vaccination public pro-
grams, and relationship status of women. There were
no safety concerns in vaccinated women within the
study; however, more information and safety reassur-
ance to the public continue to be relevant for
informed decision making.ACKNOWLEDGMENTS
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